At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 421 enrolled
Drug / intervention
Verdiperstat +1 moredrug
Likely dose
Verdiperstat 300mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy (M-STAR Study)
In Brief
A Phase 3 clinical trial evaluating Verdiperstat and Placebo for Multiple System Atrophy. Completed, enrolled 421 participants across 48 sites in 6 countries.
Detailed Summary
The purpose of this study is to compare the efficacy of verdiperstat (BHV-3241) versus placebo in participants with Multiple System Atrophy
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple System Atrophy
CountriesAustria, France, Germany, Italy, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedMay 2019
Enrollment StartJul 2019
Primary CompletionJul 2021
Study CompletionJun 2022
TodayJul 2026
First PostedMay 16, 2019
Enrollment StartJul 29, 2019
Primary CompletionJul 29, 2021
Study CompletionJun 30, 2022
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 7.1 years ago
Interventions
Verdiperstatdrug
300mg 2 oral tablets, twice daily
Placebodrug
Matching placebo